Prometheus: the Supreme Court redefines the patentability of diagnostic inventions.
Recent Pat DNA Gene Seq
; 6(3): 193-6, 2012 Dec.
Article
em En
| MEDLINE
| ID: mdl-22812581
ABSTRACT
The United States Supreme Court recently issued an opinion regarding the patentability of claims directed to diagnostic methods in Mayo Collab. Service v. Prometheus Lab., Inc. In this opinion, the Supreme Court held that correlations between metabolite levels in the human body and either therapeutic efficacy or adverse effects are unpatentable laws of nature. It further found that a patent claim to a method including such a correlation is unpatentable if the remainder of the claim contains only conventional and well-known steps. The Prometheus decision creates uncertainty regarding the scope of patentable subject matter, particularly in the fields of diagnostic and personalized medicine, that will remain until future cases apply this new doctrine.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Patentes como Assunto
/
Decisões da Suprema Corte
/
Serviços de Diagnóstico
Idioma:
En
Ano de publicação:
2012
Tipo de documento:
Article